Cell-activated wound dressing releases healing proteins in preclinical tests.
Researchers report a scaffold material that uses the pulling force of cells to release and activate growth factors, with effects on blood vessel growth shown in cell cultures and in rats.
A research team has described a biomaterial that lets cells trigger the release of growth factors, the proteins that guide tissue repair. The work is published on nature.com. The system is called traction-force-activated payloads, or TrAPs. These are aptamer constructs (short strands of nucleic acid) attached to scaffold materials.
Each aptamer binds a specific growth factor and holds it in an inhibited state. One end is anchored to the scaffold, and the other carries a cell-adhesive peptide called RGD. When a cell grips that peptide and pulls, the aptamer unfolds, and the growth factor is released and becomes active. The authors say current approaches depend on passive diffusion, that the proteins last only minutes in the body, and that high doses are therefore needed, which raises the risk of side effects.
In a cell assay, human microvascular endothelial cells grew sprouts on beads. Beads carrying TrAPs preloaded with VEGF-A produced total sprout length about 200% longer, on average, than control groups, and sprouts about 100% thicker than those in the scrambled-peptide group. In rats with a 6 mm femoral defect, collagen sponges with VEGF-TrAPs led to more blood vessels than an empty gap or a plain sponge after 3 weeks. The vessels were also larger than in all three comparison groups. Each group had five femurs.
The team also tested empty TrAPs with no added growth factor. Cells secreting VEGF-A on such materials formed longer sprouts, which the authors read as capture, concentration and redelivery of the cells' own protein. Adding HGF-targeting TrAPs increased cell migration. The abstract reports that TrAPs harvested multiple growth factors from cells, injury sites and blood lysate in rat femur, mouse skin and ex vivo human skin, at doses orders of magnitude below current clinical standards.
The paper notes limits. The rats were healthy, so native VEGF-A was probably already present, and several mechanistic explanations are the authors' hypotheses. Bone growth was unchanged over 12 weeks, as expected for a treatment aimed at blood vessels, and no adverse events were seen in the VEGF-TrAP group. All work described was in cells, animals or ex vivo human skin.
Note: The headline calls this a wound dressing. The page describes TrAPs as aptamer constructs attached to biomaterial scaffolds, such as collagen sponges implanted in rat bone defects, not a finished dressing.
At a Glance
- Paper published 2026-07-27 describes traction-force-activated payloads (TrAPs) on biomaterial scaffolds.
- In cell sprouting assays, VEGF-TrAPs gave about 200% longer total sprout length than control groups.
- Rat femoral defect of 6 mm: VEGF-TrAP collagen sponges produced larger vessels than all comparison groups at 3 weeks.
- No adverse events or effect on bone growth appeared in the VEGF-TrAP group over 12 weeks in rats.
- Testing covered rat femur, mouse skin and ex vivo human skin; no human patient results are reported.
Sources
This brief was written by Brightside Report from the reporting linked above. Spot an error? Request a correction.